Autologous Bone Marrow Transplantation in Advanced Hodgkin's Disease

References

• Gisselbrecth C., Brice P., Lepage E., et al. Autologous bone marrow transplantation in Hodgkin's disease. Nouv. Rev. Fr. Hematol. 1990; 32: 5–7
   PubMedGoogle Scholar
• Nadermanee A., O'Donnell M. R., Snyder D. S., et al. High dose chemotherapy with or without total body irradiation lollowed by autologous hone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381–1390
   PubMed Web of Science ®Google Scholar
• Bierman P. J., Bagin R. G., Jagannath S., et al. High dose chemotherapy followed by autologous hcmatopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann. Oncol. 1993; 4: 767–773
   PubMed Web of Science ®Google Scholar
• Bierman P. J., Vose J. M., Armitage J. O. Autologous transplantation for Hodgkin's disease: coming of age'?. Blood 1994; 83: 1161–1164
   PubMed Web of Science ®Google Scholar
• Reece D. E., Connors J. M., Spinelli J. J., et al. lntenaive therapy with cyclophosphamide, carmustine, etopo-side ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Williams S. F., Bitran J. D. The role of high-dose and autologous hone marrow reinfusion in the treatment of Hodgkin's disease. Hematol. Oncol. Clin. North. Am. 1989; 3: 319–330
   PubMed Web of Science ®Google Scholar
• Harding M., Selby P., Gore M., et al. High dose chemotherapy and autologous bone niarrow transpliiritation for relapsed and refractory Hodgkin's disease. Eur. J. Cancer 1992; 28A: 1396–1400
   PubMed Web of Science ®Google Scholar
• Patti C., Maiolino I., Scime R., et al. High-dose cyclophosphamide, etoposide and BCNU (CBV) with autologous stein cell rescue in malignant lymphomas. Eur. J. Haemrtol. 1993; 51: 18–24
   PubMed Web of Science ®Google Scholar
• Chopra R., McMillan A. K., Linch D. C., et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. B. lond 1993; 81: 1137–1145
   Google Scholar
• Taylor P. R., Jackson G. H., Lennard A. L., et al. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group. Br. J. Cancer 1993; 67: 383–387
   PubMed Web of Science ®Google Scholar
• Gulati S., Bennett C., Phillips J., et al. GM-CSF as an adjunct to autologous bone marrow transplantation. Stem Cells Doyt. 1993; 11: 20–25
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. 0. Bone marrow transplantation for Hodgkin's disease and lymphoma. Annu. Kev., Med 1993; 44: 255–263
   Google Scholar
• Armitage J. O. Early hone marrow transplantation in Hodgkin's disease. Ann. Oncol 1994; 5(Suppl 2)S161–S163
   PubMedGoogle Scholar
• Desch C. E., Lasala M. R., Smith T. J., et al. The optimal timing of autologous hone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J. Clin. Oncol. 1992; 10: 200–209
   PubMed Web of Science ®Google Scholar
• Vose J. M., Kennedy B. C., Bierman P. J., et al. Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies. Cancer 1992; 69: 784–789
   PubMed Web of Science ®Google Scholar
• Bastion Y., Tigaud J. D., Coiffier B. Treatment of relapses and failures in disseminated Hodgkin's disease. Presse Med. 1991; 20: 1733–1736
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Santoro A. Current issues in the management of advanced Hodgkin's disease. Blood Rev. 1990; 4: 69–70
   PubMed Web of Science ®Google Scholar
• Goldstone A. H., McMillan A. K. Conceptual problems in relation to dose escalation in the first remission of Hodgkin's disease. Ann. Oncol 1992; 3(Suppl 4)91–93
   PubMedGoogle Scholar
• Ahmed T. Autologous marrow transplantation for Hodgkin's disease current techniques and prospects. Cancer Invest. 1990; 8: 99–106
   PubMed Web of Science ®Google Scholar
• Bierman P. J., Armitage J. 0. Role of autotrans-plantation in Hodgkin's disease. Hemurol. Oncol. Clin. Norrh.m. 1993; 7: 591–611
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Wolff S. N., Herzig R. H., et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blond 1989; 73: 2086–2092
   PubMed Web of Science ®Google Scholar
• Sureda A., Brunet S., Lopez J. J., et al. High-dose chemotherapy with bone marrow rescue for treatment of Hodgkin's disease. Leukemia and Lymploma 1992; 7(Suppl)29–31
   PubMed Web of Science ®Google Scholar
• Yahalom J., Gulati S., Shank B., et al. Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. Inr. J. Radiar. Oncol. Bid. Phys. 1989; 17: 915–922
   PubMed Web of Science ®Google Scholar
• Reece D. E., Barnett M. J., Connors J. M., et al. Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1991; 9: 1871–1879
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Linch D. C., Singer C. R., et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344
   PubMed Web of Science ®Google Scholar
• Spinolo J. A., Jagannath S., Velasquez W., et al. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. Leukrmia and Lymphornu 1993; 9: 71–77
   PubMed Web of Science ®Google Scholar